List of Figures
Figure 1: Biosimilars Approval Pathways in the US and Europe, Global Biologics Market Forecast, ($bn), 2009–2016
Figure 2: Biosimilars Approval Pathways in the US and Europe, Share of Top 25 Biologics By Therapeutic Class, 2009
Figure 3: Biosimilars Approval Pathways in the US and Europe, Growth for Biologics, 2010
Figure 4: Biosimilars Approval Pathways in the US and Europe, Share of Top 25 Biologics By Production System, 2008
Figure 5: Biosimilars Approval Pathways in the US and Europe, Biologics Under Development by Therapeutic Class, Global, 2008
Figure 6: Biosimilars Approval Pathways in the US and Europe, Biologics Under Development by Disease Category, Global, 2008
Figure 7: Biosimilars Approval Pathways in the US and Europe, Comparison of Small Molecule Drugs and Biologics
Figure 8: Biosimilars Approval Pathways in the US and Europe, Difference Between the Distribution Chains for Small Molecule and Biologic Drugs
Figure 9: Biosimilars Approval Pathways in the US and Europe, Medicare Coverage for Biologic Drugs, 2009
Figure 10: Biosimilars Approval Pathways in the US and Europe, Imminent Biosimilar Opportunities, 2010
Figure 11: Biosimilars Approval Pathways in the US and Europe, Comparison of Biosimilars With Generics, 2010
Figure 12: Biosimilars Approval Pathways in the US and Europe, Development Costs and Timelines for a Biosimilar, 2010
Figure 13: Biosimilars Approval Pathways in the US and Europe, Challenges and their Solutions in Biopharmaceutical Manufacturing, 2010
Figure 14: Biosimilars Approval Pathways in the US and Europe, Global, Market Forecasts, ($m), 2009–2016
Figure 15: Biosimilars Approval Pathways in the US and Europe, the US, Market Forecasts, ($m), 2009–2016
Figure 16: Biosimilars Approval Pathways in the US and Europe, Europe, Market Forecasts, ($m), 2009–2016
Figure 17: Biosimilars Approval Pathways in the US and Europe, Japan, Market Forecasts, ($m), 2009–2016
Figure 18: Biosimilars Approval Pathways in the US and Europe, Global, hGH Biosimilars Market Forecasts, ($m), 2009–2016
Figure 19: Biosimilars Approval Pathways in the US and Europe, Global, EPO Biosimilars Market Forecasts, ($m), 2009–2016
Figure 20: Biosimilars Approval Pathways in the US and Europe, Global, G-CSF Biosimilars Market Forecasts, ($m), 2009–2016
Figure 21: Biosimilars Approval Pathways in the US and Europe, Global, Interferon alfa Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Figure 22: Biosimilars Approval Pathways in the US and Europe, Global, Interferon beta Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Figure 23: Biosimilars Approval Pathways in the US and Europe, Global, Insulin and Insulin Analogs Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Figure 24: Biosimilars Approval Pathways in the US and Europe, Global, TNF alfa Inhibitor Biosimilar Market Opportunity Analysis,($m), 2009–2016
Figure 25: Biosimilars Approval Pathways in the US and Europe, Global, Monoclonal Antibodies Against Cancer Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Figure 26: Biosimilars Approval Pathways in the US and Europe, Global, Expected Market Split in 2016
Figure 27: Biosimilars Approval Pathways in the US and Europe, Key Success Factors in the Biosimilar Industry, 2010
Figure 28: Biosimilars Approval Pathways in the US and Europe, Comparison of Capabilities of Market Entrants, 2010
Figure 29: Biosimilars Approval Pathways in the US and Europe, Drivers and Restraints, 2010
Figure 30: Biosimilars Approval Pathways in the US and Europe, Rising Expenditure on Pharmaceuticals, 2010
Figure 31: Biosimilars Approval Pathways in the US and Europe, Increase in Elderly Population Indicates Rising Healthcare Expenses, 2010
Figure 32: Biosimilars Approval Pathways in the US and Europe, Inflation in Prescription Drug Prices in the US , 2010
Figure 33: Biosimilars Approval Pathways in the US and Europe, Costs of Development, Manufacturing and Approval of Biosimilars by Cell Culture Type, ($m), 2010
Figure 34: Biosimilars Approval Pathways in the US and Europe, Objectives of Biosimilar Legislation and Regulatory Frameworks, 2010
Figure 35: Biosimilars Approval Pathways in the US and Europe, the US, Regulatory Bodies for Biologics, 2010
Figure 36: Biosimilars Approval Pathways in the US and Europe, Drug Development and Approval Process, 2010
Figure 37: Biosimilars Approval Pathways in the US and Europe, the US, Evolution of Regulatory Pathway, 2010
Figure 38: Biosimilars Approval Pathways in the US and Europe, the US, Impact of Data Exclusivity Period on Biosimilars Development, 2010
Figure 39: Biosimilars Approval Pathways in the US and Europe, the US, Patent Litigation Provisions in BPCIA – Round 1, 2010
Figure 40: Biosimilars Approval Pathways in the US and Europe, the US, Patent Litigation Provisions in BPCIA – Round 2, 2010
Figure 41: Biosimilars Approval Pathways in the US and Europe, Key Issues Discussed at FDA’s Public Hearing on Biosimilars, 2010
Figure 42: Biosimilars Approval Pathways in the US and Europe, the US, Drivers and Barriers for the Biosimilars Market, 2009–2016
Figure 43: Biosimilars Approval Pathways in the US and Europe, Europe, Drug Approval Process, 2010
Figure 44: Biosimilars Approval Pathways in the US and Europe, Europe, Evolution of Regulatory Pathway for Approval of Biosimilars, 2010
Figure 45: Biosimilars Approval Pathways in the US and Europe, Europe, General and Product Specific Guidelines for Biosimilars, 2010
Figure 46: Biosimilars Approval Pathways in the US and Europe, Europe, Approval Process for Biosimilars, 2010
Figure 47: Biosimilars Approval Pathways in the US and Europe, Europe, Data and Market Exclusivity Periods, 2010
Figure 48: Biosimilars Approval Pathways in the US and Europe, Europe, Comparability Exercises, 2010
Figure 49: Biosimilars Approval Pathways in the US and Europe, Europe, Number of Biosimilar Applications, 2004–2009
Figure 50: Biosimilars Approval Pathways in the US and Europe, Europe, Key Issues Facing Biosimilars Market, 2010
Figure 51: Biosimilars Approval Pathways in the US and Europe, Europe, Drivers and Barriers for the Biosimilars Market, 2009–2016
Figure 52: Biosimilars Approval Pathways in the US and Europe, the UK, Drivers and Barriers for the Biosimilars Market, 2009–2016
Figure 53: Biosimilars Approval Pathways in the US and Europe, Germany, Drivers and Barriers for the Biosimilars Market, 2009–2016
Figure 54: Biosimilars Approval Pathways in the US and Europe, France, Drivers and Barriers for the Biosimilars Market, 2009–2016
Figure 55: Biosimilars Approval Pathways in the US and Europe, Spain, Drivers and Barriers for the Biosimilars Market, 2009–2016
Figure 56: Biosimilars Approval Pathways in the US and Europe, Italy, Drivers and Barriers for the Biosimilars Market, 2009–2016
Figure 57: Biosimilars Approval Pathways in the US and Europe, Japan, Evolution of Regulatory Pathway, November 2009
Figure 58: Biosimilars Approval Pathways in the US and Europe, Japan, Drivers and Barriers for the Biosimilars Market, 2009–2016
Figure 59: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Sandoz, 2010
Figure 60: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Sandoz, SWOT, 2010
Figure 61: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Teva, 2010
Figure 62: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Teva, SWOT, 2010
Figure 63: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Hospira Inc, 2010
Figure 64: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Hospira, SWOT, 2010
Figure 65: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Dr. Reddy’s Laboratories, 2010
Figure 66: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Dr. Reddy’s Laboratories, SWOT, 2010
Figure 67: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Biocon, 2010
Figure 68: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Biocon, SWOT, 2010
Figure 69: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Biopartners, 2010
Figure 70: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Biopartners, SWOT, 2010
Figure 71: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Watson Pharmaceuticals, 2010
Figure 72: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Watson Pharmaceuticals, SWOT, 2010
Figure 73: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, STADA Arzneimittel AG, 2010
Figure 74: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, STADA Arzneimittel AG, SWOT, 2010
Figure 75: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Reliance Life Sciences, 2010
Figure 76: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Reliance Life Sciences, SWOT, 2010
Figure 77: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Intas Biopharmaceuticals, 2010
Figure 78: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Intas Biopharmaceuticals, SWOT, 2010
Figure 79: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Celltrion Inc, 2010
Figure 80: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, Celltrion Inc, SWOT, 2010
Figure 81: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, 3SBio Inc, 2010
Figure 82: Biosimilars Approval Pathways in the US and Europe, Major Biosimilar Players, 3SBio Inc, SWOT, 2010